These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 16186303)
21. Beyond the Label: Ensuring That Drug Benefits Outweigh Risks in the Food and Drug Administration's Risk Evaluation and Mitigation Strategy Program. Epstein MS; Shah ED; Deepak P; Kushnir VM Am J Gastroenterol; 2019 Jul; 114(7):1017-1019. PubMed ID: 31033521 [No Abstract] [Full Text] [Related]
22. Anticipated US approval for rosiglitazone and pioglitazone. Diabetes Obes Metab; 1999 May; 1(3):181-2. PubMed ID: 11220298 [No Abstract] [Full Text] [Related]
23. Drug safety. Planned study of Avandia in doubt after FDA review. Kean S Science; 2010 Jul; 329(5990):375. PubMed ID: 20651123 [No Abstract] [Full Text] [Related]
24. Drug safety special: the safety catch. Wadman M Nature; 2005 Mar; 434(7033):554-6. PubMed ID: 15800591 [No Abstract] [Full Text] [Related]
25. Two-stage drug approval would reduce the risks. Frantz JA Nature; 2005 May; 435(7039):143. PubMed ID: 15889063 [No Abstract] [Full Text] [Related]
26. Draft FDA guidance for assessing the safety of glucose lowering therapies: a missed opportunity? Khunti K; Davies MJ; Marx N; Buse JB Lancet Diabetes Endocrinol; 2020 Oct; 8(10):810-811. PubMed ID: 32946819 [No Abstract] [Full Text] [Related]
27. Lessons from the glitazones. Saint Raymond A; Le Courtois P Lancet; 2001 Oct; 358(9289):1274. PubMed ID: 11675098 [No Abstract] [Full Text] [Related]
28. The UGDP and the FDA audit. Am Fam Physician; 1979 Jul; 20(1):67. PubMed ID: 377929 [No Abstract] [Full Text] [Related]
29. Pancreatic safety of incretin-based drugs--FDA and EMA assessment. Egan AG; Blind E; Dunder K; de Graeff PA; Hummer BT; Bourcier T; Rosebraugh C N Engl J Med; 2014 Feb; 370(9):794-7. PubMed ID: 24571751 [No Abstract] [Full Text] [Related]
30. Novel diabetes drugs to face higher hurdles? Opar A Nat Rev Drug Discov; 2007 Sep; 6(9):687-9. PubMed ID: 17907340 [No Abstract] [Full Text] [Related]
31. Diabetes drug may be associated with increase in risk of bladder cancer. Stephenson J JAMA; 2011 Jul; 306(2):143. PubMed ID: 21750286 [No Abstract] [Full Text] [Related]
32. US FDA approves three new drugs for Type 2 diabetes. Bond T Expert Rev Clin Pharmacol; 2013 Mar; 6(2):101. PubMed ID: 23593719 [No Abstract] [Full Text] [Related]
33. Academic perspectives on the United States Food and Drug Administration's guidance for industry on diabetes mellitus. Hennekens CH; Hebert PR; Schneider WR; O'Brien P; Demets D; Borer JS Contemp Clin Trials; 2010 Sep; 31(5):411-3. PubMed ID: 20601161 [TBL] [Abstract][Full Text] [Related]
34. Rosiglitazone approved for treatment of type 2 diabetes. Miller JL Am J Health Syst Pharm; 1999 Jul; 56(13):1292, 1294. PubMed ID: 10683120 [No Abstract] [Full Text] [Related]
35. FDA considers data confidentiality for diabetes drugs. Traynor K Am J Health Syst Pharm; 2014 Oct; 71(19):1607-8. PubMed ID: 25225443 [No Abstract] [Full Text] [Related]